Most Read Articles
Stephen Padilla, 04 Sep 2019
Use of sodium glucose cotransporter 2 (SGLT2), as compared with dipeptidyl peptidase 4 (DPP4), inhibitors appears to reduce the risk of heart failure and any-cause death without major cardiovascular events in the primary intention-to-treat analysis, according to a study.
Pearl Toh, 04 Sep 2019
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
27 Aug 2019
A once-weekly regimen of 25 mg trelagliptin is effective and safe for type 2 diabetes mellitus (T2DM) patients with severe renal impairment or end-stage renal disease, reports a new study.
Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Intrauterine exposure to oral contraceptives marginally affects pubertal timing

08 Sep 2019

Children exposed to oral contraceptives (OCs) early in pregnancy tend to start puberty and achieve some pubertal milestones at an earlier age, although the magnitude of effect is small and imprecise, a study has found.

The analysis included 15,800 children born during 2000–2003 into the Danish National Birth Cohort, grouped according to maternal use of combined OC pills or progestin-only pills reported around gestational week 17: no exposure (reference; n=11,828), exposure 4 months before conception (n=3,518) and exposure in early pregnancy (n=454). Children self-assessed pubertal status by completing web-based questionnaires from 11 years and biannually throughout puberty.

Intrauterine exposure to OCs showed a tendency toward slightly earlier mean age of achieving some individual pubertal milestones and overall pubertal timing. Specific milestones included voice break (months, −3.8; 95 percent CI, −6.5 to −1.0) and first ejaculation (months, −2.9, −5.9 to 0.1) in boys, and menarche (months, −1.9, −4.0 to 0.3) and Tanner breast stages in girls. The mean age difference for overall pubertal timing was −1.4 months (−3.3 to 0.4) in boys and −0.9 months (−2.7 to 1.0) in girls.

OC exposure prior to conception was not associated with pubertal timing. Furthermore, prepubertal body mass index did not exhibit a mediating effect.

Additional studies are needed, particularly those that that can distinguish between formulations of OCs and timing of exposure in foetal life, owing to the study limitations and rarity of the exposure, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 04 Sep 2019
Use of sodium glucose cotransporter 2 (SGLT2), as compared with dipeptidyl peptidase 4 (DPP4), inhibitors appears to reduce the risk of heart failure and any-cause death without major cardiovascular events in the primary intention-to-treat analysis, according to a study.
Pearl Toh, 04 Sep 2019
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
27 Aug 2019
A once-weekly regimen of 25 mg trelagliptin is effective and safe for type 2 diabetes mellitus (T2DM) patients with severe renal impairment or end-stage renal disease, reports a new study.
Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.